BCD020 rituximab bioanalog compared to standard treatment in juvenile systemic lupus erythematosus: The data of 12 months case-control study

Table 3 Dynamics of the main indicators of the disease activity in studied groups

Reduction since the baseline of	Rituximab (n = 19)	SOCT (n = 60)	P value
Anti-dsDNA, U/L (25%; 75%)	-139.7 (106.4; 374.1)	-129.0 (81.0; 369.4)	0.75
Anti-dsDNA, U/L (25%; 75%)	-93.7 (93.1; 95.0)	-83.7 (63.2; 96.4)	0.29
SLEDAI, points	-19 (17; 23)	-10 (5.0; 15.5)	0.001
SLEDAI, %	86.9 (82.6; 100.0)	77.5 (60.0; 100.0)	0.147
Daily GCS dose, mg/kg	-0.8 (0.6; 0.9)	-0.57 (0.0; 1.0)	0.874
Daily GCS dose, %	-88 (85; 90)	-83.3 (66.7; 94.6)	0.525
Proteinuria, %	-96.7 (91.3; 100)	-100 (72.9; 100)	0.967
Daily proteinuria, g/24 h	-0.83 (0.27; 1.24)	-0.1 (0; 0.34)	0.031
Patients without active LN since BL, %	-7/8 (88)	-12/17 (71)	0.356

Anti-dsDNA: Antibody against double-stained DNA; BL: Baseline; GCS: Glucocorticosteroids; SLEDAI: Systemic lupus erythematosus disease activity index; LN: Lupus nephritis.